Skip to content

Observatoire Des Patients Atteints de Laminopathies et Emerinopathies (Observatory for PAtients With Laminopathies and Emerinopathies)

Observatoire Des Patients Atteints de Laminopathies et Emerinopathies (Observatory for PAtients With Laminopathies and Emerinopathies)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03058185
Acronym
OPALE
Enrollment
800
Registered
2017-02-20
Start date
2013-07-11
Completion date
2033-07-11
Last updated
2025-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Emerinopathies, Laminopathies

Keywords

Lamin A/C, LMNA, Emerin, EMD

Brief summary

Laminopathies and emerinopathies are complex group of rare disorders due to mutations in A-type lamins (LMNA) and Emerin (EMD) genes. Among them, disorders affecting skeletal and/or cardiac muscles are the most frequent clinical manifestations, with cardiac disease being a major cause of death. Remarkable progress has been made in the description of the clinical and genetic spectrum of these diseases since the 1990's. Until now, precise phenotype/genotype relations remain elusive. As for several other neuromuscular disorders, apart from symptomatic treatments, there is currently no specific treatment to prevent or slow down the progression of the disease. The OPALE registry is a multicentre web-based registry dedicated to laminopathy and emerinopathy French patients. OPALE has been approved by ethical and regulatory authorities. Its main inclusion criteria is the presence of a proven pathogenic LMNA and/or EMD gene mutation. The OPALE objectives are to provide a tool allowing detailed capture of patient genetic, neurological, cardiological, endocrinological and respiratory assessments, in order to allow i) precise disease natural history, ii) evaluation of different disease complication frequency and iii) identification of prognosis factors.

Interventions

None listed

Sponsors

Institute of Myology
CollaboratorOTHER
Assistance Publique - Hôpitaux de Paris
CollaboratorOTHER
Institut National de la Santé Et de la Recherche Médicale, France
CollaboratorOTHER_GOV
Pitié-Salpêtrière Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Presence of a proven pathogenic LMNA and/or EMD gene mutation * Regular followup in France. * Signed informed consent

Exclusion criteria

-Refusal to sign an informed consent.

Design outcomes

Primary

MeasureTime frameDescription
Comprehensive clinical evaluation of individuals with geneticaly proven mutations in LMNA or EMD genes according to the study protocol, in order to evaluate disease progressionyearly up to 10 yearsComprehensive clinical evaluation of individuals with geneticaly proven mutations in LMNA or EMD genes according to the study protocol, in order to evaluate disease progression

Countries

France

Contacts

Primary ContactCathy Chikhaoui
k.chikhaoui@institut-myologie.org+33142165873
Backup ContactHassina Bouguerra
hassina.bouguerra@aphp.fr+33142165873

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 7, 2026